Eli Lilly submitted an application with the U.S. Food & Drug Administration for the emergency use of its coronavirus antibody treatment.
Eli Lilly said the request for Emergency Use Authorization, or EUA, followed trial data showing that the experimental antibody, Y-CoV555, met both primary and secondary endpoints. The drugmaker had earlier noted the that the treatment reduced the need for hospitalization and emergency-room visits among patients with moderate coronavirus symptoms.
"Our teams have worked tirelessly the last seven months to discover and develop these potential antibody treatments," said Eli Lily's chief scientific officer Daniel Skovronsky. "We believe the data generated to date provide sufficient evidence that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes.
"Lilly is diligently working with regulators around the world to make these treatments available," he added.
Dr. Dan Fagbuyi, ER physician and biodefense expert, joined TheStreet's Katherine Ross to discuss Eli Lilly's antibody treatment.
Watch the video above for more.
You can follow Katherine Ross on Twitter at @byKatherineRoss.
Latest Videos From TheStreet and Jim Cramer:
- Jim Cramer: Shutdowns Make Running NYC Small Business Impossible
- Looking for a FAANG Alternative? Here's Where a Monday.com Investor Finds Value
- PPE and Your Portfolio: Inside a Disruptive Industry
- Jim Cramer: You Have to Sell Movie Theater Stocks
- Don't Try to Price Stocks Around the Election: Here's Why
- What to Expect From the Markets Following a Trump or Biden Victory
- Airline Stocks Fly Higher on Hopes of More Fiscal Aid